GlassScriptPhysician profile
Paul Byrne
NPI 1801885835
$9,216.03
in general payments reported to CMS, 2019-2025
34 companies · $526 in 2025
The $526 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,522 · 2020: $1,187 · 2021: $420 · 2022: $1,176 · 2023: $498 · 2024: $886 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $5,718.00 | 2019-2022 | |
| Astellas Pharma US INC | $424.46 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $413.40 | 2019-2023 | Lo Loestrin Fe |
| Biogen, INC. | $323.03 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $222.77 | 2024-2025 | Slynd |
| Organon LLC | $201.31 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $189.01 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $177.55 | 2023-2025 | |
| Avion Pharmaceuticals | $126.25 | 2019-2022 | |
| Coopersurgical, INC. | $121.10 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $112.85 | 2021-2025 | Aptima, Myosure Tissue Removal Device |
| Applied Medical Resources Corporation | $109.07 | 2024 | Gelpoint V-Path |
| Therapeuticsmd, INC. | $98.21 | 2021-2022 | |
| Agile Therapeutics, INC. | $96.66 | 2021-2024 | Twirla |
| Evofem Biosciences, INC. | $93.25 | 2021-2024 | Phexxi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85.57 | 2020-2023 | |
| Lupin INC. | $75.76 | 2019-2021 | |
| Myovant Sciences INC. | $75.40 | 2021-2022 | |
| Amgen INC. | $65.53 | 2023 | Evenity, Prolia |
| Novo Nordisk INC | $64.95 | 2021 | |
| Roche Diagnostics Corporation | $62.75 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $46.07 | 2019 | |
| Merck Sharp & Dohme LLC | $43.97 | 2019-2020 | |
| Lilly USA, LLC | $39.17 | 2024 | Zepbound |
| Allergan, INC. | $33.96 | 2019-2020 | |
| Mission Pharmacal Company | $32.37 | 2019 | |
| Scynexis, INC. | $31.62 | 2022 | |
| Amag Pharmaceuticals, INC. | $31.14 | 2019-2020 | |
| Meditrina | $28.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.00 | 2025 | |
| Mylan Pharmaceuticals INC. | $19.39 | 2021 | |
| Aspira Women'S Health INC | $17.00 | 2020 | |
| Channel Medsystems, INC. | $8.22 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.